5 completed, 1 active not recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Secondary Immune Deficiency: new trials by email Literature Review of Secondary Immune Deficiency trials Research Report on Secondary Immune Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. Cutaquig® - Primary Immune Deficiency Disorder, Secondary Immune Deficiency | Active not recruiting | University of Alberta | 36 | 2023-04-01 | 2026-05-08 | |
| The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency Gammanorm, Other Subcutaneous Immunoglobulins - Secondary Immune Deficiency | Completed | Octapharma | 102 | 2017-09-25 | 2022-03-02 | |
| Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig 20% subcutaneous immunoglobulin - Secondary Immune Deficiency | Phase 2 / Phase 3 | Completed | Rochester General Hospital | 16 | 2017-07-21 | 2021-04-19 |
| Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder Hematologic Diseases, Secondary Immune Deficiency | Completed | Universitaire Ziekenhuizen KU Leuven | 30 | 2017-06-30 | 2019-11-15 | |
| Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) HyQvia - Primary Immunodeficiency, Secondary Immune Deficiency | Completed | GWT-TUD GmbH | 156 | 2016-12-22 | 2023-09-14 | |
| Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Subcutaneous Immune Globulin (Human) (Hizentra) - Primary Immune Deficiency, Secondary Immune Deficiency | Phase 4 | Completed | CSL Behring | 26 | 2016-03-15 | 2018-02-26 |
Primary Immunodeficiency Diseases (3) · Agammaglobulinemia (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Immune System Diseases (5) · Immunologic Deficiency Syndromes (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1)
Hizentra (3) · Fluid Therapy (1) · Immunoglobulins (1) · Injections (1) · Injections, Subcutaneous (1) · Solutions (1) · gamma-Globulins (1)
CSL Behring (2) · GWT-TUD GmbH (1) · Octapharma (1) · Rochester General Hospital (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Alberta (1)
Canada (3) · France (3) · Belgium (2) · Germany (2) · Italy (2) · United States (2) · Czechia (1) · Denmark (1) · Poland (1) · Spain (1) · United Kingdom (1)
Bruce Ritchie, MD (1) · David Pittrow, MD (1) · Elie Haddad, MD (1) · Isabelle Quinti, MD (1) · Leif Hanitsch, MD (1) · Michael Borte, MD, PhD (1) · Michel Delforge, MD PhD (1) · Nizar Mahlaoui, MD (1) · S Shahzad Mustafa, MD (1)
2015 (1)